Group 1 - The company, Jiangsu Aidi Pharmaceutical Group Co., Ltd., plans to raise up to 185 million yuan through a simplified procedure to issue A-shares, primarily to acquire a 22.23% stake in its subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., for approximately 130 million yuan, and to supplement working capital with 55 million yuan [1] - Nanda Pharmaceutical specializes in thrombolytic drugs and low molecular weight heparin raw materials, making it one of the few integrated manufacturers in China holding production approvals for both raw materials and injectable formulations [2] - The acquisition of Nanda Pharmaceutical is expected to enhance the company's control over it, optimize financial performance, and maximize synergies, thereby strengthening its competitive position in the human protein sector [3] Group 2 - The stroke incidence in China is rising, with acute ischemic stroke cases projected to increase from 4.1 million in 2023 to 4.9 million by 2027, highlighting a significant unmet clinical need for effective stroke treatments [3] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035, indicating a strong demand for innovative stroke medications [3] - Aidi Pharmaceutical has maintained rapid growth in the HIV sector for three consecutive years, with the market for anti-HIV drugs in China estimated at 7 billion yuan in 2023, projected to exceed 11 billion yuan by 2027 [4] Group 3 - The company is advancing its core HIV pipeline and aims to establish a comprehensive commercialization system for new HIV drugs, addressing the significant challenge posed by the large population of HIV-infected individuals in China [4] - Aidi Pharmaceutical has made significant progress in its HIV drug pipeline, with new drugs like ACC017 and ADC118 entering clinical trials, and is also developing long-acting pre-exposure prophylaxis drugs [5] - The 55 million yuan raised will be used to support operational funding and accelerate the development of core research projects, ensuring the efficient rollout of a diverse and comprehensive HIV drug commercialization strategy [5]

智通财经APP讯，艾迪药业(688488.SH)发布公告，公司拟以简易程序向特定对象发行A股股票，募集资 金总额不超过(含)1.85亿元，扣除发行费用后的募集资金净额将用于：收购南大药业22.2324%股权、补 充流动资金。 ...

艾迪药业(688488.SH)发布公告，公司拟以简易程序向特定对象发行A股股票，募集资金总额不超过 (含)1.85亿元，扣除发行费用后的募集资金净额将用于：收购南大药业22.2324%股权、补充流动资金。 ...

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), plans to acquire a total of 22.2324% equity in its subsidiary, Nanda Pharmaceutical, from minority shareholders for a price of 130.05954 million yuan, enhancing its control and aligning with its strategic goals [1] Group 1: Acquisition Details - The company intends to purchase 19.6337% of Nanda Pharmaceutical's equity from Huatai Guoxin, 0.0987% from Daoxing Venture Capital, and 2.5000% from Yao Fandi [1] - The acquisition will be financed through the company's own or raised funds [1] Group 2: Strategic Implications - This acquisition will strengthen the company's control over Nanda Pharmaceutical, ensuring the steady implementation of its "human-derived protein raw materials - formulation integration" strategy [1] - Increasing the stake in Nanda Pharmaceutical is expected to enhance the company's performance, as the subsidiary has shown stable growth in revenue and profit in recent years [1]

格隆汇1月13日丨艾迪药业(688488.SH)公布2026年度以简易程序向特定对象发行A股股票预案，本次发 行募集资金总额不超过（含）18,500.00万元，符合以简易程序向特定对象发行股票的募集资金总额不超 过人民币三亿元且不超过最近一年末净资产百分之二十的规定；扣除发行费用后的募集资金净额将用于 以下项目：收购南大药业22.2324%股权、补充流动资金。 MACD金叉信号形成，这些股涨势不错！ ...

Core Viewpoint - The company, Aidi Pharmaceutical, has decided to terminate its plan for a specific issuance of A-shares in 2024, originally intended to raise up to 100 million yuan for working capital [1] Group 1: Termination of 2024 A-share Issuance - Aidi Pharmaceutical announced the termination of its plan to issue up to 14.5349 million shares to a specific investor, Fu Helian, for a total fundraising amount not exceeding 100 million yuan [1] - The decision was made after careful consideration of the company's actual situation and capital market factors, aiming to better align with future development plans [1] Group 2: Future Fundraising Plans - The company plans to conduct a simplified procedure for a specific issuance of A-shares in 2026, with a total fundraising target of up to 185 million yuan [1] - Of the planned amount, 130 million yuan is earmarked for acquiring a 22.2324% stake in Nanda Pharmaceutical, while 55 million yuan will be used to supplement working capital [1]

证券代码：688488 证券简称：艾迪药业 公告编号：2026-006 江苏艾迪药业集团股份有限公司 第三届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏艾迪药业集团股份有限公司（以下简称"公司"）第三届董事会第十一 次会议通知于 2026 年 1 月 10 日送达全体董事，会议于 2026 年 1 月 13 日在公司 会议室以现场结合通讯表决方式召开。本次会议由董事长傅和亮先生主持，应到 董事 9 名，实到董事 9 名。本次会议的召集和召开程序符合《中华人民共和国公 司法》和《公司章程》等相关规定。 二、董事会会议审议情况 与会董事就如下议案进行了审议，并表决通过以下事项： （二）逐项审议通过了《关于公司 2026 年度以简易程序向特定对象发行 A 股股票方案的议案》 根据《公司法》《证券法》《管理办法》等法律法规和规范性文件的有关规 定及公司 2024 年年度股东会的授权，结合公司具体情况，公司制定了本次以简 易程序向特定对象发行股票方案，董事会进行了逐项审议。 ...

人民财讯1月13日电，艾迪药业(688488)1月13日公告，公司拟以1.3亿元的价格，收购控股子公司南京南 大药业有限责任公司(简称"南大药业")少数股东持有的南大药业22.23%股权。收购完成后，公司对南大 药业的直接持股比例由51.13%增至73.36%，将进一步提升对子公司的控制力与管理效率，保证公司"人 源蛋白原料—制剂一体化"战略的稳步实施。 此外，艾迪药业公告终止2024年度向特定对象发行A股股票事项，同时披露2026年度以简易程序向特定 对象发行A股股票预案，拟募资不超1.85亿元，用于收购南大药业22.23%股权及补充流动资金。 ...

格隆汇1月13日｜艾迪药业公告，公司于2026年1月13日召开第三届董事会第十一次会议，审议通过了 《关于终止公司2024年度向特定对象发行A股股票事项的议案》等相关议案，公司决定终止2024年度向 特定对象发行A股股票事项，本事项无需提交公司股东会审议。 ...

每经AI快讯，艾迪药业1月13日晚间发布公告称，公布2026年度以简易程序向特定对象发行A股股票预 案，本次发行募集资金总额不超过（含）1.85亿元，扣除发行费用后的募集资金净额将用于以下项目： 收购南大药业约22.23%股权项目，拟投入募集资金1.3亿元；补充流动资金项目，拟投入募集资金5500 万元。 （记者 王晓波） 每经头条（nbdtoutiao）——"春节也要加班，抢在4月1日前交货"！有光伏企业在抢出口，也有企业很 纠结：白银等原材料成本激增，决策困难 ...